Delayed hypersensitivity in patients treated by curative radiotherapy. Its relation to tumor response and short-term survival.
Delayed hypersensitivity, as determined by skin reactivity to 2-4 dinitrochlorobenzene (DNCB), was tested in 112 patients prior to their undergoing curative radiotherapy. Of the strong DNCB reactors, 84% had an excellent radiation tumor response, while only 48% of the negative reactors had an equivalent response. Almost twice as many strong DNCB reactors were alive and free of disease (NED) at 6 months (70% vs. 38% for nonreactors). Similarly, the positive DNCB reactors had a median survival of 18 months, compared to 10 months for the nonreactors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004137:Dinitrochlorobenzene; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy; D006257:Head; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D011446:Prospective Studies; D012882:Skin Tests; D014565:Urogenital Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy
D004137:Dinitrochlorobenzene